Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Cash from Financing Activities (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Cash from Financing Activities data on record, last reported at $5.1 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 243.32% year-over-year to $5.1 million; the TTM value through Sep 2025 reached $12.0 million, up 78.58%, while the annual FY2024 figure was $5.7 million, 16.18% up from the prior year.
  • Cash from Financing Activities reached $5.1 million in Q3 2025 per COEP's latest filing, up from $125100.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $6.1 million in Q1 2025 and bottomed at -$2.7 million in Q4 2022.
  • Average Cash from Financing Activities over 4 years is $2.0 million, with a median of $1.5 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: tumbled 103.73% in 2023, then surged 755.77% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at -$2.7 million in 2022, then soared by 164.1% to $1.8 million in 2023, then crashed by 58.21% to $731971.0 in 2024, then surged by 591.83% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $5.1 million in Q3 2025, $125100.0 in Q2 2025, and $6.1 million in Q1 2025.